INSIGHTS ON CLINICAL TRIAL DESIGN

• Executing A Complex Global Breast Cancer Trial In A Rapidly Evolving Treatment Landscape

  See how rapid site activation, strong oncology site relationships, and adaptive protocol management kept a complex global cancer trial on track amid evolving standards of care.

• Blueprint For Early Phase Clinical Pharmacology Studies In Dermatology

  Explore the landscape of dermatological drug development through a comprehensive framework for rational early-phase dermatological trials, centered around five foundational pillars.

• Phase-Appropriate Signal Detection In Clinical Trials

  Are your trial safety methods right for your phase? Learn a framework that keeps medical judgment central, avoids overreading sparse early data and catches rarer risks as studies grow.

• Multi-Regional Clinical Trials: The Latest Guidance From FDA

  Conducting multi-regional clinical trials (MRCTs) is essential for accelerating oncology drug development and ensuring broader patient access. However, differences across regions can impact findings.

• Incorrect Clinical Trial Enrollment Is Preventable. A Tale Of Three Case Studies

  6/5/2026

  See how three clinical trials used centralized eligibility review to accelerate enrollment, eliminate enrollment-based protocol deviations, and keep studies on track, even at a global scale.

• Leveraging Biomarkers In Early PK/PD Studies

  7/9/2025

  Integrating biomarkers into early clinical studies is crucial to determine whether a new therapy engages its biological target, triggers the intended PD effects, and shows early signs of efficacy.

• Learning About The Sensors In myMedidata

  9/16/2025

  Learn how sensor data and advanced analytics can transform clinical research and enable your study to overcome data challenges, improving patient care.

• The Hidden Complexity Of Ophthalmic Protocol Requirements

  3/21/2025

  Explore the critical role of meticulously planning ophthalmic assessments in clinical trials, highlighting their potential risks and complexities.

• The Psychedelic Setback: What MDMA Rejection Taught Drug Developers

  6/25/2026

  Psychedelic compounds show real promise for PTSD, but proving it requires solving unblinding, bias, and safety gaps in trial design.